Researchers at the Broad Institute of MIT and Harvard and Cyrus Biotechnology have now engineered two CRISPR nucleases, Cas9 and Cas12, to mask them from the immune system. The team identified ...

The company, which utilises CRISPR-Cas9 and other computationally engineered nuclease technologies to develop novel antiviral therapies, will now invest the money into developing its research and ...

SuperNuclease ® is a highly effective endonuclease that has been genetically engineered to efficiently ... cell DNA was significantly reduced by nuclease treatment of the lentiviral supernatant.

The favorable written opinion states that the BRAIN-Engineered-Cas (BEC) nucleases for which patent protection is sought under the Patent Corporation Treaty (PCT) with an earliest priority date of ...

The company’s pipeline of products based on allogeneic chimeric antigen receptor (CAR)-T cells are engineered ex vivo ... Precision is developing an ARCUS nuclease that targets chronic hepatitis ...

Get Instant Summarized Text (Gist) CRISPR nucleases, Cas9 and Cas12, have been engineered to evade immune detection, addressing a key challenge in CRISPR-based therapies. By identifying and ...